The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression by Neijenhuis, M.K. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/174843
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
RESEARCH ARTICLE Open Access
The effect of disease severity markers on
quality of life in autosomal dominant
polycystic kidney disease: a systematic
review, meta-analysis and meta-regression
Myrte K. Neijenhuis1, Wietske Kievit1, Ronald D. Perrone2, Jeff A. Sloan3, Patricia Erwin4,5,
Mohammad Hassan Murad6, Tom J. G. Gevers1, Marie C. Hogan7 and Joost P. H. Drenth1*
Abstract
Background: Little is known about determinants of quality of life (QoL) in autosomal dominant polycystic kidney
disease (ADPKD). Recent studies suggest that QoL in ADPKD is determined by more factors than mere renal
function. We investigated the effect of ADPKD on QoL and evaluated how Qol is affected by disease severity
markers renal function, kidney volume and liver volume.
Methods: We performed a systematic review, meta-analysis and meta-regression analyses of cohort studies
and randomized controlled trials investigating patient-reported QoL in adult patients with ADPKD not yet on
dialysis. EMBASE, MEDLINE, and Web of Science were searched to August 2015 without language restrictions.
Two investigators independently reviewed title, abstracts and full text of potentially relevant citations to determine
eligibility. We compared pooled QoL summary scores of ADPKD patients using a random-effects meta-analytic model.
These scores were compared with mean and age-corrected reference scores of the general population. In a meta-
regression analysis, we investigated the univariate effect of renal function, kidney volume and liver volume on QoL.
Results: We included nine studies in meta-analysis including 1623 patients who completed the SF-36 questionnaire.
Pooled physical (PCS) and mental component scores (MCS) of the SF-36 of individuals with ADPKD were lower than
those of the reference population (45.7 vs. 50.0 and 47.8 vs. 50.0 points, both P < 0.001). QoL of ADPKD patients
remained lower after comparison with age-corrected reference values (age 35–44 year; PCS 52.2, MCS 49.9 points,
both P < 0.05). Larger liver volume negatively impacted PCS (P < 0.001) and MCS (P = 0.001), whereas there was
no association with renal function (PCS P = 0.1, MCS P = 0.9) and kidney volume (PCS P = 0.5, MCS P = 0. 5). Total
liver and kidney volume had no impact on PCS (P = 0.1), but did have impact on MCS (P = 0.02).
Conclusions: QoL reported by non-dialysis patients with ADPKD is impaired compared to the general population.
Large liver volume was the most important factor that diminishes QoL.
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Background
A growing body of evidence on QoL in chronic kidney
disease (CKD) suggests that quality of life (QoL) is not
determined merely by renal function [1–3]. The pres-
ence of anemia and cardiovascular disease can also have
substantial negative impact on QoL [1–3]. In autosomal
dominant polycystic kidney disease (ADPKD), anemia
[4, 5], and cardiovascular diseases [6] are less frequent
compared to other kidney diseases. This suggests that
other disease-specific factors may contribute to QoL
impairment in ADPKD [7].
ADPKD is defined by progressive renal cyst develop-
ment, leading to enlarged kidneys, kidney failure and
eventually end stage kidney disease [8]. Kidney manifes-
tations of ADPKD include acute and chronic pain,
hematuria, nephrolithiasis, and cyst infection [9]. This
disease is associated with a range of extrarenal manifes-
tations, including liver cysts which occur in the majority
of patients, mitral valve abnormalities and intracranial
aneurysms [10]. Clinical symptoms in ADPKD seems to
be a function of kidney and liver size, and are not
primarily related to kidney function decline [11].
Large kidney and liver volumes compress adjacent
organs and structures leading to symptoms that may im-
pair QoL such as fullness, early satiety and pain [12, 13].
Further, it has been demonstrated that kidney enlarge-
ment occurs well before renal function decline and
severe polycystic liver disease may also occur in early
stage ADPKD [8, 12, 14]. This indicates that physical
manifestations of ADPKD which may adversely affect
QoL are present before renal function deficits are de-
tected [8, 13].
How disease severity markers, such as renal function,
kidney volume and liver volume, affect QoL in ADPKD
is uncertain. Several studies showed at best very weak
correlations among these variables [12–16]. Most studies
included a selected population of patients with ADPKD
based on either chronic kidney disease (CKD) stage or
organ volumes which limits drawing robust conclusions
on the relation between disease severity markers and
QoL across the clinical spectrum of ADPKD. Under-
standing factors that impact QoL of individuals with
ADPKD can guide treatment decisions and improve ho-
listic patient-centered care beyond simply monitoring
renal function [7].
This systematic review and meta-analysis investigates
the effect of ADPKD on QoL. As secondary outcome,
we assessed the effect of the disease severity markers
renal function, kidney volume and liver volume on QoL
in ADPKD.
Methods
This systematic review was conducted according to
a research protocol registered in the PROSPERO
international prospective register of systematic reviews
(registration number CRD42015026428). We reported
this systematic review in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [17].
Eligibility criteria
We included studies that met the following inclusion
criteria: (1) cohort studies and randomized controlled
trials (RCTs); (2) adult patients >18 years, with a diag-
nosis of ADPKD [18] and; (3) use of a patient-reported
outcome to reflect QoL. We excluded studies that (1)
used a patient-reported outcome without summary score
of individual questions, (2) studies that investigated
QoL with a one-item visual analogue scale (VAS) only
as it often provides insufficient QoL information [19],
(3) longitudinal intervention studies that provided no
baseline QoL scores and, (4) studies that did not re-
port original data.
Search strategy
A medical librarian (P.E.) developed and executed a sys-
tematic search combining the search terms and Medical
Subject Headings for ‘ADPKD’ and ‘renal function’ or
‘kidney volume’ or ‘liver volume’ and ‘quality of life’ in
the electronic databases of EMBASE, MEDLINE, and
Web of Science. Letters to the editor, editorials and case
reports were excluded. Additional file 1: Table S1 pro-
vides an example of one full electronic search. We
searched for conference abstracts in abstract books of
the American Society of Nephrology (ASN), World
Congress of Nephrology (WCN) and the European Renal
Association – European Transplant and Dialysis Associ-
ation (ERA-EDTA) published between August 2012 and
August 2015 and unpublished studies in the database of
clinicaltrials.gov. Reference lists of included articles and
relevant reviews were screened for additional leads. Two
investigators (M.N. and M.H.) independently reviewed
title and abstracts to determine eligibility. Disagreements
between M.N and M.H. were included for full text re-
view. Subsequently, both investigators screened full text
of eligible studies and disagreement between M.N and
M.H. was resolved by discussion with a third author
(T.G.). Corresponding authors of original articles were
contacted for additional information if needed. Cohen’s
kappa was calculated as measure of agreement on study
selection. A value between 0.40–0.59 was considered as
fair agreement, 0.60–0.74 as good agreement and 0.75 or
higher as excellent agreement [20].
Quality assessment
Since there is no standard tool available to assess the
risk of bias for uncontrolled studies, we used items de-
rived from the Newcastle-Ottawa Scale to assess risk of
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bias on study and outcome level [21]. We scored the ca-
tegories (1) study population selection; (2) completeness
of reported results; (3) used patient-reported outcome
instrument; (4) recall period and; (5) response rate as
low or high risk of bias followed by an overall conclu-
sion of the risk of bias (low, moderate or high risk of
bias) as judged by two independent reviewers.
Outcome
Primary outcome was summary QoL score measured
with a patient-reported outcome instrument at baseline.
We included studies in meta-analysis and meta regres-
sion that used a patient-reported outcome measure that
was used in 3 or more studies [22]. Scores of indi-
viduals with ADPKD were compared with reference
values if available.
We expected that the SF-36 was used in most studies,
as it is the most frequently used patient-reported out-
come worldwide and is often used in kidney studies
[23, 24]. The SF-36 is a generic QoL measure that
composes of eight domains (physical functioning,
role-physical, bodily pain, general health, social func-
tioning, vitality, role-emotional, and mental health)
that can be summarized in two composite scales; the
physical component scale (PCS) and mental compo-
nent scale (MCS) [25]. These summary scores can re-
duce type I errors by avoiding multiple testing and
can distinguish better between different health state
levels than the eight separate domains [26]. A higher
PCS or MCS score indicate a better QoL. Population-
based reference values for both component scales are
set to 50 points with a standard deviation of 10
points [27]. We calculated component scores of the
SF-36 using US norm values, as previous studies
showed a similar impact of chronic diseases on QoL
across different countries [28].
Data extraction
M.N. extracted data of the included articles using a
standardized data collection form to record (1) study
characteristics: first author, year of publication, coun-
try of origin, study design and number of participants;
(2) patient characteristics: age, gender, chronic kidney
disease (CKD) stage as defined by KDIGO [29], mean
renal function defined as (estimated) GFR in ml/min/
1.73m2, median kidney and liver volume measured
with volumetric software or ellipsoid formula (kidney
volume only); (3) QoL data: baseline summary scores
of patient-reported outcome instruments. For studies
that presented only serum creatinine as measure of
renal function, we calculated the eGFR with the
chronic kidney disease epidemiology collaboration
(CKD-EPI) formula and Modification of Diet in Renal
Disease (MDRD) formula [30]. Total liver and kidney
volume was calculated by summing liver and kidney
volumes. In RCTs, baseline QoL scores of both pla-
cebo and intervention groups of RCTs were pooled.
QoL data of subgroups stratified by renal function
was handled separately. Summary scores were recal-
culated when the original authors used a scoring
algorithm which was different from the official pub-
lished scoring manual. W.K. reviewed the complete
dataset for completeness and accuracy.
Data analysis
To calculate the effect of ADPKD on QoL, we per-
formed a pre-specified analysis using a random-effects
meta-analytic model of DerSimonian and Laird [31].
The random effect model is used if large heterogeneity
is expected and adjusts for differences in study size.
Heterogeneity was assessed using I2 statistics and a cut-
off value of I2 > 50% was considered as substantial
heterogeneity [32]. When population-based reference
values of included patient-reported outcomes were avai-
lable, we compared whether the pooled mean scores of
ADPKD patients were significantly different compared
to the general population with an independent t-test.
When the pooled mean of ADPKD patients was signifi-
cantly lower than the general population, we compared
the pooled means with age-corrected values to assess
whether this difference remained significant. Additional
sensitivity analyses including high quality studies only
were performed to assess the influence of study quality.
To explore the effect of disease severity markers on
QoL, we performed a pre-specified univariate meta-
regression analysis in which the dependent variable was
QoL score (PCS or MCS) and the independent variables
were renal function, kidney volume, liver volume and
total liver and kidney volume. As additional exploratory
analysis, we performed the primary meta-regression ex-
cluding studies with severe liver involvement (defined as
median liver volume > 3000 mL, based on a previous
published classification [14]). Kidney and liver volumes
have a skewed distribution and were logarithmically
transformed. If a study provided no standard deviation
(SD), standard error (SE) or interquartile range (IQR) of
the summary QoL score, we imputed SD from the mean
SD of other included studies. As a sensitivity analysis,
we compared the results of the meta-regression of eGFR
calculated with the CKD-EPI with eGFR calculated with
the MDRD formula. Analyses were performed using the
statistical program OpenMetaAnalyst [33]. For all ana-
lyses, P < 0.05 was considered statistically significant.
Results
From a total of 373 unique articles identified by our sys-
tematic search, 11 studies matched our inclusion criteria
[13, 15, 16, 34–41]. Figure 1 shows the PRISMA flow
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diagram with specified reasons for exclusion. There was
excellent agreement between the two reviewers on study
selection (Cohen’s Kappa 0.89). We found only two
studies that investigated QoL in patients with ADPKD
on dialysis (n = 108 and n = 5 respectively), which pre-
vented a reliable meta-analysis in this subgroup [15, 34].
We contacted eight authors for additional information
that was not published in the original articles and received
relevant data from six of them [15, 34–36, 38, 39]. Four
studies included a mixed population of patients with
isolated polycystic liver disease (ADPLD) and polycystic
liver disease as extrarenal manifestation of ADPKD
[35, 36, 39, 40]. For all these studies, we obtained se-
parate ADPKD group data by contacting the authors.
Eight studies used the SF-36 as patient-reported out-
come and one study used the KDQOL-SF1.3, a combined
questionnaire of the SF-36 and 43 kidney disease-specific
questions. The gastrointestinal symptom scale was admi-
nistrated together with the SF-36 or EQ-5D in three stu-
dies [36, 40, 41]. As there is no validated total score of the
gastrointestinal symptoms scale and the EQ-5D was used
in only two studies, this resulted in exclusion of two stu-
dies for meta-analysis [40, 41]. Other patient-reported
outcomes administrated together with the SF-36 were
used in less than three studies and were also excluded
from further analyses (see Table 1). After applying these
eligibility criteria, only studies that used SF-36 data were
eligible for inclusion.
Characteristics and quality of included studies
Table 1 describes the characteristics of the nine studies
included in meta-analysis [13, 15, 16, 34–39]. The
majority were longitudinal interventional studies (n = 7),
including three randomized controlled trials. The nine
studies included 1623 non-dialysis patients. At least 753
patients had CKD stage 1–2 and 478 CKD 3–4. There
was insufficient individual patient data on the renal
function of 363 patients to distinguish between CKD stage
1–4. One study (n = 29) did not provide renal function of
the included patients [37], resulting in 1594 available pa-
tients to assess the impact of renal function on QoL.
Seven studies reported kidney volumes (n = 1238) of the
included patients [13, 15, 16, 35–37, 39]. Five studies
reported liver volume (n = 1057), [13, 15, 35, 36, 39]
including four studies with severe polycystic liver disease
patients (median liver volume > 3000 mL) [15, 35, 36, 39].
The SD of the PCS and MCS was imputed in four studies.
Patients were on average 44 years and 45% was male.
Pooled mean (e)GFR was 58 mL/min/1,73m2 (95% CI 47
to 69), kidney and liver volumes were respectively
1465 mL (95% CI 1146 to 1784) and 3599 mL (95% CI
3010 to 4187). This indicates enlargements of approxi-
mately 4 and 2.5 times compared to normal kidneys
(300 mL for females and 400 mL for males) and livers
(1400 mL for females, 1700 mL for males), respectively.
A detailed quality assessment of the studies is presented
in Additional file 1: Table S2. There was a low risk of bias
in the majority of the studies (n = 8) and one study was
rated as having a high risk of bias (insufficient information
on study population selection and very low response rate).
QoL in ADPKD
Figure 2 shows the results of the pooled SF-36 scores of
the PCS (A) and MCS (B). The mean PCS of individuals
Fig. 1 PRISMA Flow-diagram of study inclusion
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with ADPKD was 45.7 points (95% CI 42.7 to 48.7),
although there was significant heterogeneity (I2 95.4%,
P < 0.001). This was significantly different from the
mean score of the general population (PCS 50 points
95% CI 49.6 to 50.4, P < 0.001). On the MCS, patients
scored 47.8 points (95% CI 45.7–49.8), with again large
heterogeneity (I2 90.7%, P < 0.001). Also this score was
lower compared to the general population (PCS 50
points, 95% CI 49.6 to 50.4, P < 0.05). Compared
with age-corrected reference values (age 35–44 year;
(PCS 52.2, 95% CI 51.5 to 52.8 and MCS 49.9 points,
95% CI 49.1 to 50.7, both P < 0.001), QoL of ADPKD
patients remained significantly lower. Sensitivity ana-
lysis including high quality studies only showed no
differences in pooled scores compared to the analyses
including all studies.
The relationship between markers of disease severity and
QoL in APDKD patients
The relationship of the disease severity markers renal
function, kidney volume, liver volume and total liver and
kidney volume on PCS is shown in Fig. 3. Larger liver
volume negatively impacted PCS (ß = −10.7, 95% CI -16.4
to −5.0, P < 0.001). We observed no significant effect of
renal function (ß = 0.1, 95% CI -0.03 to 0.2, P = 0.1),
kidney volume (ß = 2.5, 95% CI -5.2 to 10.3, P = 0.5) and
total liver and kidney volume (ß = −10.2, 95% CI -22.3 to
1.8, P = 0.10). On MCS, larger liver volume (ß = −4.7, 95%
CI -7.5 to −1.8, P = 0.001) and total liver and kidney vol-
ume (ß = −5.6, 95% CI -10.0 to −1.1, P = 0.02) had signifi-
cant impact, while renal function (ß = −0.005, 95% CI -0.08
to 0.07, P = 0.9) and kidney volume (ß = −1.5, 95% CI -5.6
to 2.5, P = 0. 5) did not (Additional file 2: Figure S1). Sensi-
tivity analyses showed similar results using the MDRD for-
mula to calculate eGFR or when low quality studies were
excluded.
In studies with mild to moderate liver involvement
(median liver volume ≤ 3000 mL), renal function did
have a negative impact on PCS (ß = 0.1, 95% CI 0.05 to
0.2, P = 0.02), but there was no effect of kidney volume
(ß = −7.8, 95% CI 23.2 to 7.7, P = 0.3; Fig. 4). On the
MCS, neither renal function (ß = −0.02, 95% CI -0.11 to
0.08, P = 0.8) nor kidney volume (ß = −2.9, 95% CI -10.2
to 4.3, P = 0.4) had impact (Additional file 3: Figure S2).
Discussion
We show that ADPKD negatively impacts QoL, particu-
larly through the effect of the disease on parameters of
the physical domain. Individuals with ADPKD had lower
PCS and MCS compared to population-based reference
values. We found large heterogeneity across QoL of
individuals with ADPKD. In the primary meta-regression
performed to explain this heterogeneity, larger liver volu-
me, but not renal function and kidney volume, correlated
with lower physical and mental components of health
status in ADPKD. However, after exclusion of studies of
patients with large liver volumes, lower renal function was
also correlated with lower PCS.
Large liver volume had a negative effect on QoL in
ADPKD, indicating that liver volume is an important
parameter that should be accounted for when investiga-
ting QoL in this population. However, the strong female
predominance in severe polycystic liver disease studies
(74 vs. 53%, P < 0.001) and inclusion of slightly older
patients (mean age 51 ± 10 vs. 43 ± 12 year, P = 0.24) in
studies with mild to moderate liver involvement can also
contribute to QoL impairment in these patients [27].
Comparing general reference values of younger males
(35–44 years) with older females (45–54 years), resulted
in a mean difference of 4.5 and 0.2 points for PCS and
MCS, respectively. The loss of QoL in the liver volume
meta-regression analysis was larger than these diffe-
rences (ß = −10.7 points per logarithm for PCS and
ß = −4.7 for MCS), suggesting an independent additional
effect of liver volume on QoL.
Fig. 2 Pooled physical (a) and mental (b) component score of the SF-36 of individuals with ADPKD. ADPKD patients (black line) scored lower than
the general population (grey line)
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Our exploratory analysis suggests that QoL declines
during progression towards CKD stage 5 in patients
without severe polycystic liver disease. This indicates
that renal function is also an important factor of QoL in
ADPKD, but this effect was negated by the strong im-
pact of liver volume in the total group. An independent
patient data analysis with correction for liver volume is
necessary to draw definitive conclusions about the role
of renal function and kidney volume on QoL.
A previous study showed that patients with larger kid-
ney volume reported more pain that impacted their daily
life compared to patients with smaller kidneys [13]. We
did not find a significant impact of kidney volume on
QoL, possibly because only a limited number of studies in
our meta-analysis included patients with large kidney vo-
lumes. A large observational study including 450 ADPKD
patients of CKD stages 1–4 (DIPAK) is currently being con-
ducted in the Netherlands. This study may reveal whether
large kidney volume contributes to a decrease in QoL.
A strength of this study is that we conducted this
systematic review by rigorously following a published
protocol with pre-specified analyses. Meta-regression
including disease severity markers provides insight into
the heterogeneous results of QoL found in earlier studies.
Fig. 3 Meta-regression analysis of the physical component score of the SF-36 with the factors (a) (e)GFR (ml/min/1.73m2), b Kidney volume, c
Liver volume and d Total liver and kidney volume. Volumes are presented on a logarithmic scale. Barros et al., [34]; Hogan et al., [35]; Keimpema
et al., [36]; Lee et al., [37]; Miskulin et al., [13] subgroup eGFR 20–44*; Miskulin et al., [13] subgroup eGFR 45–60; Miskulin et al., [13] subgroup eGFR
≥60; Rizk et al., [16]; Simms et al., [38] subgroup eGFR <30; Simms et al., [38] subgroup eGFR 30–60; Simms et al., [38] subgroup eGFR >60; Suwabe
et al., [15]; Temmerman et al., [39]. *No kidney and liver imaging in this subgroup, not included in figures b-d
Fig. 4 Meta-regression analysis of the physical component score of the SF-36 with the factors (a) (e)GFR (ml/min/1.73m2) and b Kidney volume
after exclusion of studies with severe liver involvement. Volumes are presented on a logarithmic scale. Barros et al., [34]; Lee et al., [37]; Miskulin et
al., [13] subgroup eGFR 20–44*; Miskulin et al., [13] subgroup eGFR 45–60; Miskulin et al., [13] subgroup eGFR ≥60; Rizk et al., [16]; Simms et al.,
[38] subgroup eGFR <30; Simms et al., [38] subgroup eGFR 30–60; Simms et al., [38] subgroup eGFR >60. *No kidney and liver imaging in
this subgroup, not included in figure b
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Our study comes with a number of limitations. First,
not all studies reported values of all disease severity
markers, which limited the number of studies included
in our meta-regression analysis. Furthermore, not all po-
tential modifiers of QoL in ADPKD could be included in
this study. Earlier studies have shown that comorbidity,
the use of pain medication, presence of a cerebral
aneurysm, and lower education levels are associated with
lower QoL in this population [16, 38]. Two qualitative
studies showed that genetic guilt also might be an im-
portant factor that influences QoL [42, 43]. The lack of
detail in the articles under study precluded systematic
analysis of these factors.
Secondly, part of heterogeneity in QoL might also be
explained by study design. Most included studies were
intervention studies. Patients involved in these studies
do not resemble the general ADPKD patient population.
QoL of patients participating in intervention studies was
generally lower compared to patients from observational
studies, likely due to the reality that most interventional
studies have included patients with larger livers. How-
ever, the large variability in disease severity markers
enabled us to thoroughly investigate the impact of these
factors on QoL in individuals with ADPKD.
Third, we could include only QoL data collected with
a generic patient-reported outcome, which is likely less
sensitive to detect disease burden than disease-specific
measures [44]. On the other hand, an unpublished global
observational study of 3409 individuals with ADPKD
showed that the PCS of the SF-12, a short version of the
SF-36, could differentiate QoL between CKD 1 and CKD
3a, while the disease-specific ADPKD Impact Scale
could differentiate CKD 1 from CKD stage 3b [45]. This
suggests that the PCS distinguishes between individuals
with ADPKD in a slightly earlier phase than the disease-
specific ADPKD Impact Scale. The MCS of the SF-12
was unable to differentiate between CKD 1 and other
disease stages, indicating that this component score is
insensitive to change in this disease population.
This systematic review on QoL in ADPKD clearly
identified knowledge gaps. Data on QoL in patients with
ADPKD and more advanced stages of CKD were insuffi-
cient to be assessed. As liver volume appears to impact
QoL, clinicians should check liver disease severity pe-
riodically and consider liver volume reducing therapies
in severe hepatomegaly as a strategy to improve patients’
wellbeing. Indeed, research shows that reduction of liver
volume with somatostatin analogues improves QoL in
severe polycystic liver disease [46]. However, currently
data is lacking on the effect of other therapies on
QoL. In patients without severe polycystic liver di-
sease, QoL was negatively impacted by renal function.
Vasopressin V2 receptor antagonists slow renal func-
tion decline, but additional studies should investigate
whether the possible positive effect on QoL is coun-
teracted by side effects such as aquaresis.
Conclusion
In conclusion, there is limited representative data available
on the impact of disease severity markers on QoL in
ADPKD. Existing data showed that QoL of non-dialysis
ADPKD patients is impaired compared to the general
population. Large liver volume was the most important
factor that diminishes QoL.
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